{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:59:01Z","timestamp":1789765141271,"version":"4.0.1"},"reference-count":41,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of tisotumab vedotin-tftv (TV), a first-in-class vectorized anti-tissue factor (TF) antibody-drug conjugate (ADC), for the treatment of recurrent or metastatic cervical cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search of ClinicalTrials.gov, Embase, and PubMed was conducted using the terms tisotumab vedotin AND cervical cancer from inception to June 30, 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All applicable publications, package inserts, meeting abstracts, and clinical trials involving TV in the treatment of cervical cancer were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>TV is a fully human TF-specific monoclonal antibody conjugated to monomethyl auristatin E, which serves as a highly potent cytotoxic payload. In the pivotal phase II InnovaTV 204 clinical trial, TV demonstrated an objective response rate of 24% (95% confidence interval [CI], 16%-33%). The mean duration of response was 8.3 months. Common toxicities included abdominal pain, alopecia, conjunctivitis, constipation, decreased appetite, diarrhea, dry eye, epistaxis, nausea\/vomiting, and peripheral neuropathy. Unique and\/or serious adverse events warranting careful monitoring include ocular complications, hemorrhaging, peripheral neuropathies, fetal-embryo toxicity, pneumonitis, and immunogenicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Recurrent or metastatic cervical cancer remains a high-risk disease with limited treatment options. Using ADCs to target tumors with aberrant expression of TF appears to be a viable treatment strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>TV is the first Food and Drug Administration\u2013approved TF-directed ADC. With a manageable safety profile and promising anticancer activity, TV warrants consideration as a novel targeted agent for the treatment of recurrent or metastatic cervical cancer. Further studies are required to determine the optimal place in therapy for TV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221118370","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T01:12:21Z","timestamp":1660353141000},"page":"585-596","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":24,"title":["A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-6103","authenticated-orcid":false,"given":"Nathan","family":"Heitz","sequence":"first","affiliation":[{"name":"Jackson-Madison County General Hospital, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0463-1224","authenticated-orcid":false,"given":"Samuel C.","family":"Greer","sequence":"additional","affiliation":[{"name":"Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7032-0398","authenticated-orcid":false,"given":"Zachery","family":"Halford","sequence":"additional","affiliation":[{"name":"Pharmacy Practice, Union University College of Pharmacy, Jackson, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"bibr1-10600280221118370","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21708."},{"key":"bibr2-10600280221118370","unstructured":"Cancer Institute Cancer Stat Fact: Cervical Cancer. Published 2020. Accessed June 22, 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/cervix.html."},{"key":"bibr3-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJQ356."},{"key":"bibr4-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1159\/000214920."},{"key":"bibr5-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32470-X."},{"key":"bibr6-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.30667."},{"key":"bibr7-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2002-0342."},{"key":"bibr8-10600280221118370","unstructured":"Nicole McMillian N, Angela Motter M, Frederick P, et al. NCCN Guidelines Version 1.2022 Cervical Cancer. Published online 2021. Accessed June 22, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf."},{"key":"bibr9-10600280221118370","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6723."},{"key":"bibr10-10600280221118370","unstructured":"US Food and Drug Administration (FDA). FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer. Accessed June 18, 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer."},{"key":"bibr11-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0798."},{"key":"bibr12-10600280221118370","unstructured":"TIVDAK (tisotumab-vedotin-tftv) [package insert]. Bothell, WA: Seagen Inc.; 2021."},{"key":"bibr13-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6324."},{"key":"bibr14-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000130465.23430.74."},{"key":"bibr15-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2351."},{"key":"bibr16-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1038\/SJ.BJC.6603552."},{"key":"bibr17-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.24.11832"},{"key":"bibr18-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2482."},{"key":"bibr19-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U"},{"key":"bibr20-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04318.x."},{"key":"bibr21-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.177428."},{"key":"bibr22-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2440."},{"key":"bibr23-10600280221118370","unstructured":"Pilot H, McElroy EAJr, Reid JM, et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 1999;5(3):525. Accessed June 22, 2022. https:\/\/aacrjournals.org\/clincancerres\/article\/5\/3\/525\/199270\/Phase-I-Trial-of-Dolastatin-10-NSC-376128-in."},{"key":"bibr24-10600280221118370","unstructured":"Madden T, Tran HT, Beck D, et al. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res. 2000;6(4):1293-1301. Accessed June 22, 2022. https:\/\/aacrjournals.org\/clincancerres\/article\/6\/4\/1293\/288162\/Novel-Marine-derived-Anticancer-Agents-A-Phase-I."},{"key":"bibr25-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.22334."},{"issue":"2","key":"bibr26-10600280221118370","first-page":"353","volume":"31","author":"Shnyder SD","year":"2007","journal-title":"Int J Oncol"},{"key":"bibr27-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1021\/MP500762U."},{"key":"bibr28-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1038\/nbt832."},{"key":"bibr29-10600280221118370","unstructured":"ADCETRIS (brentuximab vedotin) [package insert]. Bothell, WA: Seagen Inc.; 2022."},{"key":"bibr30-10600280221118370","unstructured":"POLIVY (polatuzumab vedotin-piiq) [package insert]. South San Francisco, CA: Genentech Inc.; 2020."},{"key":"bibr31-10600280221118370","unstructured":"PADCEV (enfortumab vedotin-ejfv) [package insert]. Bothell, WA: Seagen Inc.; 2021."},{"key":"bibr32-10600280221118370","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061332."},{"key":"bibr33-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1111\/CAS.15443."},{"key":"bibr34-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30859-3."},{"key":"bibr35-10600280221118370","unstructured":"Berger MJ, Anand S, Barbour S, et al. NCCN Guidelines Version 2.2022 Antiemesis. Published online 2022. Accessed June 30, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf."},{"key":"bibr36-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.02.010."},{"key":"bibr37-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00056-5."},{"key":"bibr38-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2962."},{"key":"bibr39-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5507"},{"key":"bibr40-10600280221118370","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2016.10.002."},{"key":"bibr41-10600280221118370","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073559."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221118370","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221118370","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221118370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:17:02Z","timestamp":1777375022000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221118370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1177\/10600280221118370"],"URL":"https:\/\/doi.org\/10.1177\/10600280221118370","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]}}}